|POZEN Submits Final MT 100 Mouse Carcinogenicity Study Results to FDA|
CHAPEL HILL, N.C., Mar 6, 2002 /PRNewswire-FirstCall via COMTEX/ -- POZEN Inc. (Nasdaq: POZN), a pharmaceutical development company with a portfolio of candidates for the treatment of migraine, announced today that it has submitted the final results of its six-month mouse carcinogencity study for its lead product candidate, MT 100, to the Food and Drug Administration (FDA). The final results confirmed preliminary findings that indicated that MT 100 was not carcinogenic in the test species, p53 transgenic mice. The preliminary results were submitted to the FDA in February.
MT 100 is being developed as an oral, first-line treatment for migraine pain and associated symptoms. The effectiveness of the product candidate has been demonstrated in numerous Phase II and Phase III clinical studies involving thousands of patients. Last year the company announced that MT 100 provided comparable efficacy with fewer incidences of side effects when tested against Imitrex(R), the worldwide market leader.
North Carolina-based POZEN Inc. is a pharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas. POZEN's initial focus is on developing products for migraine therapy, a global market expected to exceed $2.6 billion this year. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN."
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" proviWe do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
POZEN is on the Internet at www.pozen.com